Fact CheckerSign in

NCT05853809Completed

Primary Care Asthma FeNO Trial

Clinical Effect of FeNO Measurement for Asthma Treatment in Primary Care: A Real-world Cluster-randomised Controlled Trial

Source: ClinicalTrials.gov · Last updated 18 Sept 2026

Brief summary (registry, in English)

Asthma is a chronic inflammatory respiratory disease that affects people of all ages and of both sexes. It is a common disease and is present in 8-10 % of the population. Despite drug treatment, many patients have poor control of their asthma with an impact on quality of life and restriction of daily activities. The purpose of this study in primary care is to investigate if measurement of airway inflammation (FeNO) can improve the treatment results and the overall care of adult patients with asthma. The main question in the study is whether the use of FeNO measurements can reduce the number of deterioration periods. The study is conducted under real clinical conditions where the effect of the intervention is measured (pragmatic intervention study). Eight to twelve primary health care centers with functional asthma / COPD clinics are selected within the Stockholm County and are randomly assigned to two groups with four to six primary health care centers each, an active group and a control group (cluster randomization). Instruments for FeNO measurements are made available to the active group and this group is also trained on FeNO measurements and how the value should be interpreted and used to control the treatment, while the control group continues to take care of their asthma patients as usual. The study can lead to improved treatment decisions and patients gaining an increased understanding of their asthma by being informed on the actual degree of inflammation in the airways. Optimized treatment can provide better asthma control with increased quality of life and fewer periods of deterioration, which results in reduced burden on healthcare and lower costs for patients and society.

Status (registry)
Completed
Study type
Interventional
Enrollment
3254 (actual)
First submitted
2 May 2023
Start date
1 Apr 2023
Primary completion date
1 Jun 2025
Lead sponsor
Region Stockholm
Diseases
Asthma
NCT number
NCT05853809

What you commit to

  • Study type: Interventional
  • Participants enrolled: 3254
  • From 1 Apr 2023 to the primary completion date, 1 Jun 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Physician diagnosed COPD (Chronic Obstructive Pulmonary Disease) according to medical record.

Who the study is looking for

  • Physician diagnosed asthma according to medical record.
  • Patients seeking advice for symptoms suggestive of asthma

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Region Stockholm
Coordinator of this site? Confirm its status
StockholmSwedenUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.